Novo Nordisk/€NOVOB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Novo Nordisk
Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, that operates in the pharmaceutical industry with a primary focus on diabetes care. The company develops, manufactures, and markets pharmaceutical products and services, with significant emphasis on insulin and GLP-1 therapy for diabetes management. Novo Nordisk is also involved in the treatment of obesity, rare blood and endocrine disorders, and growth hormone therapy. The company was founded in 1923 and has a substantial international presence, offering products in more than 170 countries. Novo Nordisk's strategic strengths include its extensive research and development capabilities, a strong product pipeline, and a deep commitment to innovation in chronic disease management.
- Ticker
- €NOVOB
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 66,700
- Headquarters
- Bagsvaerd, Denmark
- Website
- www.novonordisk.com
Novo Nordisk Metrics
BasicAdvanced
€154B
9.89
€3.50
0.35
€1.57
4.52%
Price and volume
Market cap
€154B
Beta
0.35
52-week high
€54.86
52-week low
€30.25
Average daily volume
5.4M
Dividend rate
€1.57
Financial strength
Current ratio
0.873
Quick ratio
0.642
Long term debt to equity
0.55
Total debt to equity
0.633
Dividend payout ratio (TTM)
44.64%
Interest coverage (TTM)
1,566.84%
Profitability
EBITDA (TTM)
23,234.509
Gross margin (TTM)
81.99%
Net profit margin (TTM)
35.35%
Operating margin (TTM)
48.99%
Effective tax rate (TTM)
21.72%
Revenue per employee (TTM)
€660,870
Management effectiveness
Return on assets (TTM)
18.73%
Return on equity (TTM)
59.82%
Valuation
Price to earnings (TTM)
9.891
Price to revenue (TTM)
3.493
Price to book
5.19
Price to tangible book (TTM)
11.58
Price to free cash flow (TTM)
24.078
Free cash flow yield (TTM)
4.15%
Free cash flow per share (TTM)
1.44
Dividend yield (TTM)
4.52%
Growth
Revenue change (TTM)
5.61%
Earnings per share change (TTM)
4.98%
3-year revenue growth (CAGR)
17.84%
10-year revenue growth (CAGR)
11.56%
3-year earnings per share growth (CAGR)
20.74%
10-year earnings per share growth (CAGR)
14.01%
3-year dividend per share growth (CAGR)
18.26%
10-year dividend per share growth (CAGR)
9.55%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Analyst projections of the future price of Novo Nordisk stock.
Bulls say / Bears say
Novo raised its 2026 outlook again after stronger GLP-1 sales, and second-quarter profit beat forecasts. That suggests demand and cost controls are helping to steady performance, even though the company still expects a decline for the year. (Reuters)
A phase III study found that Wegovy met its main goal in children aged six to 12 with obesity. If regulators approve use in this age group, it could broaden the medicine’s potential patient base. (Clinical Trials Arena)
Eli Lilly has taken the lead in the US market: it held 60.9% of the obesity and diabetes drug market in the second quarter, against Novo’s 38.8%. That points to a tough fight for Novo’s core growth market. (CNBC)
Even after raising its forecast, Novo expects 2026 adjusted sales and operating profit to fall by 0% to 6% at constant exchange rates. Lower US prices, tougher competition and reduced Medicaid coverage are weighing on its outlook. (Reuters)
Semaglutide, the key ingredient in Ozempic and Wegovy, faces patent expiries in the early 2030s. Reuters Breakingviews said Novo’s planned extra $23 billion in pipeline sales by 2035 may barely offset lost sales from that core franchise. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Novo Nordisk
AllEURUSDGBP
Fund name | Fund size | €NOVOB weighting |
|---|---|---|
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 1.15% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 1.15% |
Vanguard FTSE Developed Europe ex UK€VERX | €3.3B | 1.11% |
Vanguard FTSE Developed Europe ex UK$VERE | €1.4B | 1.11% |
Vanguard FTSE Developed Europe ex UK£VERX | €3.3B | 1.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.